News Industry News U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure June 26, 2019
News Daily News Same-Day Discharge Safe After Elective PCI, Canadian Study Affirms Marcus A. Banks June 25, 2019
News Features Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment Todd Neale June 25, 2019
News Daily News To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped L.A. McKeown June 25, 2019
News Daily News Genetic Data Hint at Causal Link Between High BMI and Cardiovascular Diseases Marcus A. Banks June 24, 2019
News Daily News CMS Releases Final Decision Memo on Rules for TAVR Program Reimbursement Shelley Wood June 24, 2019
News Industry News Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation June 24, 2019
News Daily News ‘People Are Pretty Optimistic’ as Renal Denervation’s Comeback Continues Todd Neale June 24, 2019
News Daily News Cardiac Cath and EP Labs: Study Shines Light on Directors’ Financial Ties to Industry Caitlin E. Cox June 21, 2019
News Daily News Rapid-Access CT Model Seeks to Increase Efficiency, Reduce Delays for Chest Pain Yael L. Maxwell June 21, 2019
News Daily News Vitamin D for CV Risk? Think Twice, Meta-analysis Confirms Marcus A. Banks June 21, 2019
News Daily News Echo for Acute MI Ups Hospital Stays and Costs, Without Boosting Outcomes Yael L. Maxwell June 20, 2019
News Daily News FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD L.A. McKeown June 20, 2019
News Conference News TVT 2019 Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery Michael O'Riordan June 20, 2019
News Daily News FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One L.A. McKeown June 19, 2019
News Conference News TVT 2019 Pascal Transcatheter Device Safe, Improves Tricuspid Regurgitation: Early Results Shelley Wood June 19, 2019
News Conference News TVT 2019 Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR Michael O'Riordan June 19, 2019